Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.

MLA

Dranitsaris, George, et al. “Low-Molecular-Weight Heparins for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer: A Systematic Literature Review of Efficacy and Cost-Effectiveness.” Journal of Oncology Pharmacy Practice, vol. 25, no. 1, Jan. 2019, pp. 68–75. EBSCOhost, https://doi.org/10.1177/1078155217727140.

APA

Dranitsaris, G., Shane, L. G., & Woodruff, S. (2019). Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness. Journal of Oncology Pharmacy Practice, 25(1), 68–75. https://doi.org/10.1177/1078155217727140

Chicago

Dranitsaris, George, Lesley G. Shane, and Seth Woodruff. 2019. “Low-Molecular-Weight Heparins for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer: A Systematic Literature Review of Efficacy and Cost-Effectiveness.” Journal of Oncology Pharmacy Practice 25 (1): 68–75. doi:10.1177/1078155217727140.